title: Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery.
abstract: The present study deals with the development of transferosomal gel containing insulin by reverse phase evaporation method for painless insulin delivery for use in the treatment of insulin dependent diabetes mellitus. The effect of independent process variables like ratio of lipids (soya lecithin:cholesterol), ratio of lipids and surfactants, and ratio of surfactants (Tween 80:sodium deoxycholate) on the in vitro permeation flux (μg/cm(2)/h) of formulated transferosomal gels containing insulin through porcine ear skin was optimized using 2(3) factorial design. The optimal permeation flux was achieved as 13.50 ± 0.22 μg/cm(2)/h with drug entrapment efficiency of 56.55 ± 0.37% and average vesicle diameter range, 625-815 nm. The in vitro insulin permeation through porcine ear skin from these transferosomal gel followed zero-order kinetics (R (2) = 0.9232-0.9989) over a period of 24 h with case-II transport mechanism. The in vitro skin permeation of insulin from optimized transferosomal gel by iontophoretic influence (with 0.5 mA/cm(2) current supply) also provided further enhancement of permeation flux to 17.60 ± 0.03 μg/cm(2)/h. The in vivo study of optimized transferosomal gel in alloxan-induced diabetic rat has demonstrated prolonged hypoglycemic effect in diabetic rats over 24 h after transdermal administration.
authors: Department of Pharmaceutics, Bengal College of Pharmaceutical Sciences and Research, Durgapur 713212, West Bengal, India.
authors: Jadupati
authors: J
authors: Malakar
authors: Suma Oomen
authors: SO
authors: Sen
authors: Amit Kumar
authors: AK
authors: Nayak
authors: Kalyan Kumar
authors: KK
authors: Sen
keywords: Gel; Hypoglycemic effect; Insulin; Iontophoresis; Permeation flux; Transdermal; Transferosome
references: Biochim Biophys Acta. 1998 Jan 19;1368(2):201-15
references: 9459598
references: Eur J Pharm Biopharm. 2010 Oct;76(2):189-99
references: 20637869
references: J Control Release. 2007 Apr 2;118(2):185-8
references: 17270303
references: Clin Pharmacokinet. 2003;42(5):461-74
references: 12739984
references: J Pharm Sci. 2008 Jan;97(1):490-505
references: 17990310
references: Int J Pharm. 2004 Jan 9;269(1):109-20
references: 14698582
references: Chem Pharm Bull (Tokyo). 2002 Jun;50(6):749-53
references: 12045327
references: Acta Pharm. 2011 Mar;61(1):25-36
references: 21406341
references: AAPS PharmSciTech. 2010 Sep;11(3):1038-44
references: 20533098
references: Biochim Biophys Acta. 2003 Aug 7;1614(2):156-64
references: 12896808
references: Adv Drug Deliv Rev. 2007 Dec 22;59(15):1521-46
references: 17881081
references: Technol Health Care. 2007;15(4):237-45
references: 17673833
references: J Pharm Pharmacol. 1999 Oct;51(10):1123-34
references: 10579683
references: ISRN Pharm. 2011;2011:780150
references: 22389858
references: Int J Biol Macromol. 2011 Nov 1;49(4):784-93
references: 21816168
references: Int J Pharm. 2003 Mar 26;254(2):271-80
references: 12623203
references: Diabetes Technol Ther. 2002;4(4):479-88
references: 12396742
references: Biochim Biophys Acta. 2002 Aug 19;1564(1):5-8
references: 12100989
references: Int J Pharm. 2007 Aug 16;341(1-2):97-104
references: 17499949
references: Expert Opin Drug Deliv. 2006 Nov;3(6):727-37
references: 17076595
references: Biomaterials. 2000 Jul;21(14):1499-507
references: 10872779